MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Here are details of MinervaX‘s latest funding round :
🚀 Launch
/
🏭 Industry
Biotechnology
🧠Management
Per Fischer (CEO), Lidia Oostvogels (CMO), Anders Vadsholt (CFO), Bengt Johansson Lindbom (CSO), Bjørn Kantsø (CTO)
💸 Funding & Investors
INVESTMENT (October 2023) | €54 million |
INVESTORS (October 2023) | The funding included investment from new investors EQT Life Sciences and Orbimed. Existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest, also participated in this round. |
🎯 Funding purpose
Boost the development of a novel prophylactic vaccine against Group B Streptococcus, or GBS.
🌐 Country HQ
The Netherlands (Copenhagen)